5 / 41
Notes:
Volume 6, Issue 4 (Suppl)
Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 58
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6
th
International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4
th
EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Hawthorn
berry extract lowers kynurenic acid and anthranilic acid formation
Berthold Kepplinger
1
, Halina Baran
1,2
*, Carina Kronsteiner
1,3
and
Mirosław Więcek
4
1
Karl Landsteiner Research Institute Mauer, Austria
2
Veterinary Medical University Vienna, Austria
3
Germany; 4Friends of Nature Society IWA, Poland
Background:
Hawthorn
berry “haws” are used to make wine, jelly and flavor brandy and this plant has been used as a remedy
for heart problems and also to treat Alzheimer’s disease. Since elevated kynurenine metabolism has been documented in patients
with cardiovascular problems and also in several brain pathologies including dementia we searched the biochemical properties of
Hawthorn
extract with respect to kynurenic acid (KYNA) and anthranilic acid (ANA) formation. KYNA is an endogenous metabolite
of tryptophan degradation and is an antagonist of the glutamate ionotropic EAA and of the nicotine cholinergic receptors. KYNA and
ANA, both influence the mitochondria respiratory parameters. We questioned whether
Hawthorn
drink has an ability to influence
KYNA and ANA formation in the rat tissues, in an
in vitro
study as we have observed with other anti-dementia drugs.
Methods:
The activities of the KYNA synthesising enzyme kynurenine aminotransferase II (KAT II) and ANA synthesising
enzyme kynureninase in rat liver homogenates were analysed in the presence of different amount of
Hawthorn
drink (N= 5) and in
respectively controls (N=5). Formed KYNA and ANA were measured using a HPLC and enzymatic method in the presence of 100
µM L-kynurenine, 70 µM pyridoxal 5’-phosphate and 150 mM Tris-acetate buffer, pH 7.4. The blanks were obtained by using
tissue which has been heat inactivated for 30 min in a boiling water bath. As a comparison drug to block KAT II activity we used
D-cycloserine in the assay, too (Eur Neuropsychopharmacol. 2014 24(4): 639-44).
Results:
Hawthorn
drink dose-dependently and significantly reduced KAT II activity of rat liver homogenate. Furthermore,
Hawthorn
drink exerted a dose-dependent inhibition of rat kynureninase activities, too. The inhibitory effect of
Hawthorn
drink
was more pronounced for KAT II than for kynureninase under assay conditions. Under used assay conditions
Hawthorn
extract and
D-cycloserine exerted similar dose-dependent inhibitory effect on KYNA synthesis.
Discussion:
This study for the first time demonstrates the ability of
Hawthorn
berry to lower KYNA and ANA formation in rat liver
homogenate. Components of
Hawthorn
berry extract are able to affect pyridoxal-5-phosphate complex causing a lowering of KYNA
and ANA formation. It is to assume that the inhibitory effect can be seen in other tissue homogenates, as well. We propose
Hawthorn
extract as a drink susceptible of therapeutic exploitation in disorders associated with enhanced KYNA and ANA synthesis in the
periphery and in the CNS particularly in diseases with cardiovascular problem and/or with memory impairment and dementia. We
believe that frequent use of this berry extract can prevent the development of pathological condition with mostly significant advantage
of use such as a lack of side effects. This study suggests anti-dementia action for
Hawthorn
berry due to lowering of KYNA formation.
halina.baran@neuro-lab.euHalina Baran et al., Clin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-026